AI, macrocyclization, and oral-peptide platforms broaden the discovery pipeline

Unnatural Products and other platform companies continue combining machine learning, automated synthesis, macrocyclization, and screening for larger or orally delivered peptides. Ashland’s Permexa remains a concrete oral-GLP-1 formulation signal, but clinical, regulatory, manufacturing, partnership, and commercial validation remain limited.